Jonathan W. Chapman

FDA investigator

Appears on 11 documents from 2014 to 2021, most often at sites in China. Most often cites written procedures; deviations (21 CFR 211.100).

11
Documents on file
4.6
Observations per 483
2014
First seen
2021
Most recent

What they cite most

From 46 observations

Activity by year

2014: 1, 2015: 1, 2016: 2, 2017: 3, 2019: 3, 2021: 1

Where

China 4 · Maryland 4 · Virginia 3

Is Jonathan W. Chapman coming to your site?

Our team writes custom reports before an inspection: what this investigator cites most, how they write it up, and how your site's history compares, in one brief you can circulate.

Ask about any investigator in Claude or ChatGPT with the AI connector.

Inspection history

11 documents, newest first
FirmOpen
483 WuXi Biologics Co. Ltd.Apr 2, 2021 · Mashan, China
483 Zhejiang Huahai Pharmaceutical Co., Ltd.Jun 28, 2019 · Linhai, China
483 Zhejiang Huahai Pharmaceutical Co., Ltd.May 31, 2019 · Linhai, China
483 Hainan Shuangcheng Pharmaceuticals Co., Ltd.Apr 24, 2019 · Haikou City, China
483 Pharmaceutics International, Inc.Oct 27, 2017 · Cockeysville, Maryland
EIR Stressa IncorporatedAug 17, 2017 · Buena Vista, Virginia
483 Barr Laboratories LLCApr 14, 2017 · Forest, Virginia

About this profile

What does Jonathan W. Chapman inspect?

Jonathan W. Chapman appears on 11 documents on file covering 9 sites, most often in China.

What do they cite most often?

21 CFR 211.100 (written procedures; deviations), followed by 21 CFR 211.67 and 21 CFR 211.192.

Can I read the observations?

Each document page previews the opening words of every observation. The full documents are available to buy, one at a time or together.

How current is this profile?

The most recent document on file for Jonathan W. Chapman is dated Apr 2, 2021.

FDA Investigator Jonathan W. Chapman: 483s & Inspections · FDA Intel